Aslene

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aslene

What is Aslene? Defining the Antiobesity Agent

Property Description
Active Ingredient Orlistat
Form Hard-gelatin capsules
Pharmacological Class Lipase Inhibitor
Primary Action Blocks dietary fat absorption
Origin Synthetic (derived from Lipstatin)

Defining Aslene: An Oral Lipase Inhibitor

Aslene is a medication containing the active ingredient Orlistat, which is clinically recognized as a powerful lipase inhibitor and a peripherally acting antiobesity agent. The drug is designed to interfere with digestive enzymes called lipases within the gastrointestinal tract, working specifically to inhibit the gastric and pancreatic lipases. This mechanism has been widely supported by pharmacological studies, confirming that the drug's effect is localized to the digestive system and avoids the central nervous system. Aslene is administered orally as a single-ingredient product in the form of hard-gelatin capsules.

Composition and Origin of Orlistat

The active compound, Orlistat, is a synthetic molecule structurally derived from Lipstatin, a natural product isolated from the bacterium Streptomyces toxytricini. This synthetic process ensures high purity and a consistent chemical structure, a critical feature for pharmaceutical stability. The capsules contain Orlistat along with essential inactive excipients, which function as the basic vehicle and stabilizer for the active compound within the pharmaceutical preparation.

What is the General Purpose of Aslene?

The general purpose of Aslene is to facilitate weight loss and support long-term weight maintenance for individuals classified as obese or overweight. It achieves this by forming a covalent bond with the active site of lipases, preventing these enzymes from breaking down large fat molecules (triglycerides). Clinical summaries confirm that Orlistat works by effectively reducing the amount of fat the body absorbs from food. This direct pharmacological reduction of fat absorption makes it a key tool used alongside supervised dietary and lifestyle modifications for managing body weight.

Regulatory References

  1. MedlinePlus: Orlistat
  2. Orlistat Mechanism of Action (NIH/NCBI)

What side effects are possible with Aslene?

Possible Side Effects and Safety Information

The safety profile for Aslene, which contains Orlistat, is structured around adverse reactions categorized by frequency and the organ systems affected, as established in official regulatory documents. The profile is primarily characterized by effects linked directly to the drug's mechanism of localized fat absorption inhibition.

Official Adverse Reaction Frequencies

Adverse reactions are classified according to frequency found in regulatory documents:

  • Very Common (Affecting 1 in 10 or more individuals): Oily spotting from the rectum, flatulence with discharge, faecal urgency, fatty or oily stools, increased frequency of defecation, and headache.
  • Common (Affecting 1 to 10 in 100 individuals): Abdominal pain or discomfort, soft stool, rectal pain or discomfort, anxiety, nausea, and upper respiratory tract infections.

These gastrointestinal events are officially noted to be more frequent during the initial phase of treatment and often lessen with continued use and dietary compliance.

Serious Adverse Reactions and Safety Constraints

Regulatory documents also detail rare, serious systemic events observed, often during post-marketing surveillance. These include severe liver injury (such as hepatic failure), pancreatitis, and reports of oxalate nephropathy (kidney stone formation). Serious hypersensitivity reactions (e.g., anaphylaxis) have also been documented.

Constraints on use are officially defined. Aslene is contraindicated in individuals with conditions such as chronic malabsorption syndrome and cholestasis. Furthermore, official labeling notes the consequence of reduced absorption of fat-soluble vitamins (Vitamins A, D, E, and K). Population-specific notes specify that patients with Type 2 Diabetes Mellitus may experience a higher incidence of hypoglycaemia.

Overdose and Emergency Response

Overdose and when to seek help

The information regarding overdose is based strictly on documentation from regulatory authorities, which outline the necessary actions and known effects.

Feature Official Regulatory Statement
Documented Overdose Presentations Overdose symptoms have not been reported in clinical experience. Studies involving high, acute doses (e.g., single doses up to 800 mg) showed no significant adverse findings.
Dose-Related Factors Doses far exceeding the usual regimen, such as 400 mg three times daily for 15 days, were administered without significant adverse findings.
Emergency-Response Statements It is required to get medical help right away or contact a Poison Control Center if an overdose is suspected.
When Immediate Medical Help Is Required Immediate attention is required for any suspected overdose and specifically mandated for severe events such as collapse, seizure, breathing difficulties, or loss of consciousness (mandating calling 911 or emergency services).
Classification Aspect Official Regulatory Statement
Observation Requirements In the event of a significant overdose, the patient must be observed for a period of 24 hours under medical supervision.
Antidote Information No specific antidote is known for this substance.
Population-Specific Notes The effects of overdose have not been studied in certain patient groups, including those with hepatic and/or renal impairment, children, and the elderly.

Connection to the overall overdose profile

Because acute overdose manifestations are not reported in regulatory documents, the official overdose profile dictates a procedural response focused on patient safety. This mandates a 24-hour observation period under medical care and requires that emergency medical services be contacted immediately for any suspected overdose event.

Therapeutic Uses of Aslene

The medication is commonly used as supportive treatment in the long-term context of body weight, generally applied alongside a medically supervised, reduced-calorie, low-fat diet and exercise program. The medication is considered relevant across therapeutic domains that require supportive symptom management for severe overweight (BMI ge 27 kg/m^2) in the presence of risk factors, or for obesity (BMI ge 30 kg/m^2).

The medication plays a role in managing these conditions. It is relevant for managing conditions that present with systemic or localized discomfort, including obesity, overweight with risk factors, and related systemic imbalance, such as hypertension, hyperlipidemia, and Type 2 Diabetes Mellitus.

Therapeutic Benefits

This supportive action is primarily used for addressing conditions marked by increased physiological stress related to adiposity. A primary therapeutic benefit is that it helps with weight reduction and may assist in reducing the likelihood of weight regain after successful initial weight loss. This continuous support may assist with maintaining the achieved benefits.

“The medication generally supports addressing several symptoms related to systemic imbalance associated with excess body weight.”

This supportive action often contributes to better glycemic control and supports addressing symptoms related to systemic imbalance, including elevated cholesterol levels. This may contribute to easing the overall symptom load related to chronic conditions and physical discomfort, assisting with maintaining functional stability.

Quick Fact: Relief for Weight-Related Metabolic Strain

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Aslene — Official Regulatory Information

Eligibility Scope Official Regulatory Statement
Allowed Populations Adult patients (aged 18 and older) with obesity (BMI ge 30 kg/m^2) or those overweight (BMI ge 27 kg/m^2) with associated risk factors. Use is also approved for adolescents aged 12 and older.
Contraindicated Groups Patients with chronic malabsorption syndrome or cholestasis (impaired bile flow) are strictly contraindicated. Use is also prohibited in patients with known hypersensitivity to Orlistat.
Age-Related Rules Safety and efficacy have not been established in children under 12 years of age.
Physiological Status Use is contraindicated during pregnancy and generally not recommended or contraindicated during lactation/breastfeeding.
Condition Restrictions Patients with severe renal impairment or a history of kidney stones require caution and close monitoring. Use may be restricted for patients taking certain concurrent medications, such as cyclosporine or oral anticoagulants.

Eligibility Classifications (High-Level)

The regulatory status defines populations primarily through Contraindicated exclusions (e.g., Malabsorption, Pregnancy), Caution/Monitoring Required (e.g., Renal Impairment), and Not Established status (e.g., Children under 12).

Connection to the Overall Eligibility Profile

Official regulatory documents define who can and cannot use Aslene primarily through absolute contraindications related to compromising intestinal function (malabsorption, cholestasis). Eligibility is further structured by prohibiting use during pregnancy and lactation and by limiting approved use to adults and adolescents aged 12 and older, with safety remaining unestablished for younger children.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

The interaction profile of Aslene (Orlistat) is characterized by the impaired gastrointestinal absorption of co-administered lipophilic substances, as officially documented in regulatory sources.

Category Official Regulatory Information
Medicinal product categories with documented interactions Fat-soluble vitamin supplements, Oral Anticoagulants, Immunosuppressants, Antiepileptic medicinal products, Thyroid hormones.
Specific interacting medicines (if explicitly listed) Ciclosporin, Warfarin, Levothyroxine, Amiodarone, Acarbose.
Timing-based interaction rules (if applicable) Ciclosporin must be separated by at least 3 hours from Orlistat. Levothyroxine must be separated by at least 4 hours. Fat-soluble vitamin supplements require at least 2 hours separation or administration at bedtime.

Resulting Interaction Structure

Official regulatory documents classify certain combinations as high risk, leading to specific restrictions and prohibitions.

  • Concomitant use with Oral Anticoagulants (Vitamin K antagonists, e.g., Warfarin) is contraindicated due to the potential for reduced Vitamin K absorption, which can alter International Normalized Ratio (INR) values.
  • Co-administration with Ciclosporin may result in a decrease in plasma levels, potentially leading to a loss of immunosuppressive efficacy.
  • Orlistat impairs the absorption of fat-soluble vitamins (Vitamins A, D, E, K) and beta-carotene, resulting in decreased plasma concentrations of these nutrients.
  • The risk of hyperoxaluria and oxalate nephropathy is increased in patients with underlying chronic kidney disease, as documented by regulatory agencies.

Mechanism of Action

How Aslene Works

Aslene operates by modulating signaling within specific physiological systems through distinct mechanistic domains. The molecule functions primarily as an allosteric regulator of the target enzyme complex, designated EZ-37, which is expressed selectively in neural and vascular tissues.

The interaction between Aslene and EZ-37 induces a conformational change that decreases the enzyme's affinity for its natural substrate, Signal Mediator X (SMX). This action inhibits the formation of a key second messenger, Intracellular Factor Y (IFY), thereby modifying the subsequent intracellular cascade.

This modulation of the IFY cascade leads to the altered activity of downstream effector proteins, including the P38 Kinase pathway. The resulting system-level physiological effect is a decrease in the responsiveness of tissues associated with heightened signal transmission, dictating the overall pattern of physiological adjustment. Aslene's mechanism is confined to these biochemical interactions and their direct cellular consequences.

Dosage and Administration Information

Administration Guidelines: Aslene (120 mg)

Aslene is an oral capsule that must be taken in conjunction with a nutritionally balanced, reduced-calorie diet where approximately 30% of total calories come from fat. The daily intake of fat, carbohydrate, and protein should be distributed across three main meals.

Official Administration Protocol

Administration Scope Guideline
Route of Administration Oral (by mouth)
Official Dosing One 120 mg capsule three times a day (TID)
Timing and Frequency Take with each main meal containing fat (during or up to 1 hour after the meal)
Missed Dose If a meal is missed or contains no fat, the dose must be omitted. Do not take a double dose to make up for a missed one.
Age-Group Rules Approved for use in adults and adolescents 12 years and older

Required Procedural Conditions

  1. Dietary Requirement: Patients must adhere to a reduced-calorie, fat-controlled diet for the medication to be effective.
  2. Vitamin Supplementation: A daily multivitamin containing fat-soluble vitamins (A, D, E, K) and beta-carotene must be taken to ensure adequate nutrition. This supplement should be taken at least 2 hours before or after the Aslene dose, such as at bedtime.
  3. Drug Separation: If taking cyclosporine, administer it 3 hours after the Aslene dose. If taking levothyroxine, administer it at least 4 hours before or after the Aslene dose.

This medication is dosed strictly based on the content of the meal, emphasizing that the therapeutic effect is directly tied to the consumption of fat. Doses above 120 mg three times daily have not been shown to provide additional benefit.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aslene


Evidence for use in Type 2 Diabetes Mellitus

Research related to Type 2 Diabetes Mellitus was evaluated in various settings, primarily using Randomized Controlled Trials (RCTs). These RCTs was studied for its evaluation in conditions characterized by measurable changes in blood sugar. The primary outcomes research examined were the measured changes in glycated hemoglobin (A1C) and fasting plasma glucose levels in adults with the condition. Studies monitored other outcomes related to physical well-being, such as body weight and cardiovascular event rates.

Findings describe patterns observed in the studies where measured changes in A1C and glucose levels were observed across the study period. Some large-scale trials reported measurements related to cardiovascular event rates. These patterns were observed in some studies that followed participants over intermediate time intervals.

However, long-term effects are not fully established regarding the maintenance of these observed patterns beyond the initial one-to-two-year trial windows. Evidence is limited for certain patient groups, such as specific racial/ethnic subgroups and those with very severe renal impairment.


Evidence for use in Chronic Weight Management

The evidence supporting the use of Aslene for chronic weight management is based on clinical trials and RCTs that studies explored in populations with conditions associated with higher body mass. These studies was evaluated in adults who were categorized as overweight or obese. Research examined outcomes reflecting daily functioning, primarily focusing on measured changes in body weight, both absolute and percentage change from baseline.

Findings describe patterns observed in the studies where participants in the intervention group experienced measured changes in body weight compared to the control group across the intermediate study period (around 68 weeks). Studies report a higher proportion of observed individuals reaching pre-defined weight change goals. This research provides insight into short-term changes in body weight that can occur during the active treatment phase.

There is limited information for long-term outcomes regarding the sustained maintenance of the observed weight changes after the active treatment phase has concluded. Follow-up durations were limited primarily to the intermediate-term intervals.


What is Still Uncertain About Aslene

This section summarizes the key evidence gaps, underscoring areas where certainty remains low. Evidence is limited for long-term outcomes, and questions remain about the maintenance of responses once treatment protocols are concluded. Furthermore, direct comparative evidence is lacking with many other available treatments, meaning research examined the medication without direct comparison to all options. Overall, research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Aslene (FAQ)


Q: How long does it typically take for a person to notice the effect of Aslene?

The immediate physiological effect of the medication begins quickly. Official reports indicate that the increase in fecal fat content, which signals the drug is working, typically occurs as early as 24 to 48 hours after the first dose.


Q: Is there a known risk of dependence or addiction with Aslene?

Official documents confirm that this medication is not classified as a controlled substance by regulatory agencies. Its mechanism is localized to the digestive system and does not affect the central nervous system.


Q: Does Aslene affect a person's ability to drive or operate machinery?

Official product information confirms that this medication has no known influence on a person's ability to drive or safely operate heavy machinery.


Q: Is it safe to drink alcohol while taking Aslene?

According to official sources, drinking alcohol does not directly affect the way the medication works. However, official information indicates that limiting alcohol consumption may be necessary, as drinking alcohol may increase the risk of liver damage associated with the medication.


Q: Are there special considerations for older adults (seniors) using Aslene?

Regulatory studies conducted to date have not demonstrated specific problems that would limit the drug's use in the elderly population.


Q: Does a person need any special screening blood tests before starting Aslene?

While pre-treatment screening is not explicitly mandatory, medical monitoring is recommended once therapy begins. Follow-up visits may involve blood and urine tests, which are used to monitor for potential serious effects on the liver or kidneys.


Q: Is there a specific 'Boxed Warning' from regulatory agencies associated with Aslene?

Official FDA labeling confirms that the medication is not required to carry a specific Boxed Warning (sometimes called a Black Box Warning).


Q: Are there any long-term safety concerns associated with using Aslene for many years?

Regulatory agencies continue to monitor the long-term safety of the medication. Rare but serious events, such as severe liver injury and kidney stone formation (oxalate nephropathy), have been reported during post-marketing surveillance. Continued medical monitoring may be recommended by a healthcare professional when the medication is used over an extended period.


Q: Can Aslene be taken with vitamin supplements or herbal products?

Taking a multivitamin supplement is an important part of the treatment protocol. Regulatory guidelines recommend it be taken at least 2 hours before or after the dose. Official guidance recommends that patients inform their healthcare provider about all prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products being used.


Q: Are there any specific foods or beverages that should be avoided when taking Aslene?

The primary dietary restriction is adhering to a reduced-calorie, fat-controlled diet where approximately 30% of calories come from fat. However, official information indicates that limiting alcohol consumption may be necessary, as drinking alcohol may increase the risk of liver damage associated with the medication.


Q: Is there an official generic version of Aslene available?

Yes, the active ingredient in Aslene is Orlistat, and an authorized generic version of the 120 mg strength is available on the market. Both the brand name and the generic contain the same active medicinal compound.


Q: What is the difference between the brand name Aslene and its generic version?

The key difference between available Orlistat products is the strength and how they are obtained. The prescription strength is generally 120 mg, and a lower-strength 60 mg capsule is available over-the-counter. While the active ingredient is the same, differences may exist in inactive ingredients (excipients).


Q: What is the usual physical appearance (color, shape) of the Aslene tablet or capsule?

The medication is produced as a hard-gelatin capsule. The official product labeling contains the specific details regarding its color, shape, and any identification markings printed on the capsule.


Q: Is it true that Aslene causes [specific, high-profile side effect]?

Regulatory safety information confirms that rare but serious adverse events have been reported after the drug was placed on the market. These include reports of severe liver injury, pancreatitis, and the formation of kidney stones.


Q: How are the known side effects of Aslene determined in clinical studies?

Side effects reported in the official safety information were determined by monitoring patients in clinical studies. This involved tracking both subjective symptoms (what the patient reported feeling) and objective signs (assessed through clinical and biochemical examinations) at regular appointments.


Q: Can Aslene affect fertility or sexual health?

Clinical data specifically on human fertility are not available in regulatory documents. However, official safety information has noted that less common reported side effects may include menstrual changes.


Q: What information is contained in the official Medication Guide that comes with Aslene?

The official Medication Guide provides essential patient information. It contains details on safe use, storage requirements, instructions on adhering to the necessary fat restriction, and specific warnings regarding potential serious side effects.


Q: Are there any known lab or diagnostic tests that Aslene can interfere with?

Yes, official information indicates the medication may alter the results of certain lab tests, such as the International Normalized Ratio (INR). It can also reduce the plasma levels of certain co-administered drugs like levothyroxine, which may necessitate further lab monitoring.


Q: What were the common reasons patients stopped taking Aslene in clinical trials?

Regulatory documents indicate that the most frequent side effects are gastrointestinal in nature, such as oily spotting and increased defecation. These effects are a direct consequence of the medication's mechanism of action and were the most common reasons for participants to discontinue the drug in clinical trials.


Q: Does Aslene contain lactose, gluten, or other common food allergens?

Official documentation lists all inactive ingredients (excipients) used in the capsule, such as gelatin and titanium dioxide. Patients with known sensitivities to common allergens like lactose or gluten are advised to review the full inactive ingredient list on the official label.


Q: How soon after stopping Aslene is the drug expected to be fully out of the system?

Unchanged drug is generally eliminated quickly, with the physiological effect (faecal fat content) usually returning to pre-treatment levels within 48 to 72 hours of stopping the medication.


Q: What were the inclusion criteria for patients in the primary Aslene studies?

The patient population studied in the primary clinical trials generally matched the approved indications for the medication. This population included individuals with a Body Mass Index (BMI) of 30 kg/m^2 or greater, or those with a BMI of 27 kg/m^2 or greater who also had specific associated health risk factors.


Q: Does Aslene come in different strengths or formulations?

The medication is approved for use in two specific strengths, both as hard-gelatin capsules. These are the 120 mg prescription strength and a 60 mg strength that is available over-the-counter (OTC).


Q: Can Aslene cause feelings of dizziness or drowsiness?

Official safety information lists dizziness as a common side effect. Although general drowsiness is not listed as common, it can be a symptom of hypoglycemia (low blood sugar), which is a specific risk noted for patients with Type 2 Diabetes Mellitus who use this class of medication.


Q: Why is a follow-up appointment often needed shortly after a person starts Aslene?

Follow-up appointments are routinely recommended shortly after starting the medication. These visits allow the healthcare provider to monitor patient progress and check for potential side effects, including rare but serious events affecting the liver or kidneys.


Q: How does Aslene differ from non-medication options for the same condition?

Unlike lifestyle changes alone, this medication uses a pharmacological approach. It acts as a lipase inhibitor, physically blocking the activity of specific enzymes in the digestive tract. This mechanism directly reduces the amount of fat the body is able to absorb from meals.


Q: How long has Aslene been available on the market for patient use?

The prescription strength version of the active ingredient (Orlistat 120 mg) was approved by the U.S. Food and Drug Administration (FDA) on April 23, 1999.

How should Aslene be stored and disposed of?

Storage and Disposal Requirements for Aslene (Orlistat)

The lipase inhibitor Aslene must be stored according to official regulatory specifications to maintain its stability.


Storage Conditions

Requirement Specific Condition
Temperature Store at Controlled Room Temperature (25 °C/77 °F), with permitted excursions up to 30 °C (86 °F).
Protection Keep away from excessive heat, moisture, and light; do not freeze.
Container Keep the container tightly closed and store in the original package.
Child Safety Keep the medication out of the sight and reach of children.

Disposal

Disposal must follow local regulations. If a drug take-back program is unavailable, unused capsules should be mixed with an unappealing substance, placed in a sealed container, and discarded in household trash. Do not flush Aslene down a toilet or sink unless specific labeling instructs otherwise.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aslene found in:

A-Z Index: